Abbott Laboratories Stock News

Abbott Laboratories didn't perform well last year, but it still has bright prospects. Netflix reported strong earnings that point to plenty of growth potential ahead.

Abbott Laboratories and Johnson & Johnson have increased their payouts annually for 52 and 61 consecutive years, respectively. Both healthcare companies have long track records of important innovation

A judge has rejected Abbott Laboratories' effort to dismiss a New York City grandmother's lawsuit claiming it misled consumers into believing its PediaSure Grow & Gain nutrition drinks were "clinicall

Novo Nordisk and Eli Lilly have generated billions of dollars in revenue selling weight loss drugs. Abbott Labs is launching a complementary product for those on the weight loss path.

Med tech stocks have been a mixed bag of results the last two years, with most moving within established trading ranges. The impact of COVID and its effect on procedure volumes were slow to dissipate,

A near 2.0% post-earnings decline in Abbott Laboratories (NYSE: ABT) warrants an investment in the health care giant, says Jim Cramer. Cramer's bullish view on Abbott stock His Charitable Trust bought

Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.

Given its better prospects, we believe Medtronic stock (NYSE: MDT) is a better pick than its peer, Abbott stock (NYSE: ABT). Abbott trades at a higher valuation multiple of 4.9x revenues vs.

While it doesn't seem like it when you're young, aging happens to everyone and therefore, so-called AgeTech stocks should benefit from inevitability. A buzzword for age-related technology, this concep

Here is how Abbott (ABT) and Akoya Biosciences (AKYA) have performed compared to their sector so far this year.

Abbott Laboratories' stock price has risen by 16.6% since October 2023, outperforming the index. The company achieved strong growth in FY23, excluding contributions from COVID testing businesses. Abbo

Abbott Laboratories NYSE: ABT share price fell following its Q4 2023 results, but investors should be cheering the news. The decline is a response to a report that was largely as expected, with the ex

Less than two years after a headline-grabbing shutdown of a baby formula plant in Michigan that fueled a national crisis, Abbott Laboratories has “reclaimed its previous market-leading position.”

Abbott (ABT) delivers better-than-expected revenues and in-line earnings for the fourth quarter of 2023.

A spot-check of early morning Q4 reports show some earnings misses and revenue beats; Tesla and others report after the close.